Fountain Life Reviews: $10,500 In, and What Is Extra

The one-sentence version

Fountain Life is the concierge ceiling of this category — whole-body and brain MRI with AI overlay, coronary CT angiography, whole genome sequencing and a hundred-plus blood markers, delivered in person at six centers by a physician-led team. Its marketing site publishes no price at all, not even a "request pricing" label; its own online store publishes them plainly: CORE $10,500 a year, APEX $21,500. It grades B, 8 points out of 14, and the deduction is not the price level — a concierge program is allowed to be expensive — but what sits outside it. The most emotionally central product on the site, the early cancer blood test, is in neither membership. The grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

Fountain Life runs six centers — Naples, Orlando, Dallas, Houston and White Plains, New York, with Miami announced — under Fountain Life Management, LLC, led by William Kapp, MD as chief executive and Dawn Mussallem, DO as chief medical officer, and co-founded by Peter Diamandis, Tony Robbins and Robert Hariri.

The product is a once-a-year diagnostic event, not a treatment protocol — the deepest screening money can buy, rather than a cheaper way to get a prescription, and that is the right frame for judging it. See longevity clinics versus lab memberships and our Fountain Life versus Human Longevity comparison.

What it actually costs

All figures verified on 26 July 2026 against Fountain Life's own pages and its own storefront.

Nothing on the marketing site. There is no pricing page. Every membership page — CORE, APEX, APEX Family — ends in "schedule a private call." Location pages carry no figures either.

Everything on its own shop. The storefront linked from the membership page lists CORE at $10,500.00 and APEX at $21,500.00, plus "final payment" items — CORE $7,000, APEX $14,500 — implying a deposit-plus-balance structure no marketing page explains. APEX Family is priced nowhere at all.

And Fountain Life's own blog gives a third number. Its article on what longevity clinics cost states: "the cost of Fountain Life starts from $20,000 annually." Its own store sells the entry tier at $10,500. Both are Fountain Life pages, and they cannot both be right.

Then the à la carte layer, also priced in the shop: therapeutic plasma exchange $10,000, placental stem cell IV therapy $1,500, an epigenetic biological-age test $750, and a multi-cancer early detection blood test at $949.

What the membership does not include

This is the part worth reading twice, because it inverts the pitch.

CORE covers 8 of the 27 listed diagnostics. APEX covers 24. APEX Family covers three: whole-body and brain MRI, DEXA and the blood panel. CORE physician access is marked "Limited", always-on care is not covered on it, and Restorative Therapeutics is "not available" to it.

The multi-cancer early detection blood test is à la carte on every tier. Fountain Life's own table marks it an extra for CORE and APEX and unavailable to APEX Family. Yet cancer is the hook the whole site hangs on — "we combine whole-body MRI, liquid biopsy (Galleri), and genetic risk profiling to detect cancers at Stage 0 or 1", and Peter Diamandis on the membership page: "imagine finding cancer at stage zero when it's most easily cured." The liquid biopsy in that sentence is $949 more. See our Galleri test review.

No membership terms are published — no minimum term, no renewal mechanics, no cancellation or refund policy, anywhere. The one terms page that exists appears to be boilerplate from an unrelated company: it refers to "an affiliate of Augment Your Immunity", points its privacy policy at another domain, offers "technology-oriented tools for smoking cessation", and names the governing law as "the laws of the State of Naples, Florida." Naples is a city. Ask for the real agreement before you pay $10,500. And if a scan finds something, no page says whether the workup, the biopsy or the treatment is inside the fee — on the evidence of the à la carte menu, it is not.

The evidence behind what it sells

Fountain Life's screening is real and it is not free of consequence, and the site presents only the first half of that.

On whole-body MRI. The 2026 systematic review and meta-analysis of whole-body MRI for opportunistic cancer detection in asymptomatic people pooled ten studies and 9,024 participants. The confirmed cancer detection rate was 1.57% (95% CI 1.22–2.03), and the authors concluded that "modest detection rates, frequent incidental findings, unstandardized protocols, and lack of long-term outcome or cost-effectiveness data limit its current clinical utility", adding that it "may lead to unnecessary investigations"¹. A separate review of 5,373 asymptomatic subjects pooled critical and indeterminate incidental findings at 32.1%, with 16.0% false positives, and found that no included study verified negative findings beyond five years²; a broader umbrella review across twenty systematic reviews makes the same point across modalities³. None of that makes the scan worthless — it means roughly one member in three should expect a finding that requires chasing, most will resolve to nothing, and the chasing is not in the fee. Fountain Life publishes no overdiagnosis or false-positive caveat on any membership page.

On the outcome statistics. A stat block repeats across roughly eight pages — "96% detect potentially life-threatening diseases before symptoms appear", "46% achieve brain age improvement, reversing accelerated aging", elsewhere "100% reported renewed energy, sharper cognition" — with no denominator, methodology or citation anywhere on the site.

On reversal. The homepage promises Restorative Therapeutics that "don't just slow aging, but could even reverse it", and APEX offers therapies that "may help reverse aging at the cellular level." No completed human trial supports that for plasma exchange, biologics or the peptide and hormone work described, though Fountain Life does state prominently that its stem cell therapy is not FDA-approved. Its intravenous nicotinamide riboside sits where the rest of this category sits: the 2026 PRISMA-guided systematic review of NAD+ covered 113 studies including 33 human trials, found clinical effectiveness "inconclusive", and reported no eligible outcomes trial of intravenous or intramuscular NAD+ for these indications at all⁴. See NAD+ for longevity, biological age tests and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if the number that matters to you is the one you pay — the real cost is the membership plus whatever the scan starts. Skip it if a 32% chance of an indeterminate finding would read as stressful rather than reassuring. And skip CORE specifically if you are buying the cancer story: it covers eight of twenty-seven diagnostics, its physician access is "limited", and the liquid biopsy is extra on it anyway. If you proceed, ask three things in writing before the deposit: the actual membership agreement, since the published terms page describes a different company; what downstream workup costs when the MRI finds something; and whether the price is $10,500 or the "from $20,000" its own blog claims.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Fountain Life takes the longevity line in full — imaging-grade diagnostics, genome sequencing and biological-age testing are exactly what this board ranks, and almost nobody here matches the depth — plus two for physician oversight and two for a care team included rather than upsold. It takes zero on price transparency: the marketing funnel publishes nothing, the store and the blog disagree, the entry tier covers under a third of the listed diagnostics, and no membership terms exist at all. Zero on pharmacy. Eight of fourteen. A B.

That is a good grade for an expensive product, and it should be read as one: the medicine here is more serious than most of what we grade, and the failure is commercial rather than clinical. Publish the price on the membership page, publish a real membership agreement, put the liquid biopsy inside the tier that sells it, and print one honest sentence about false positives — and Fountain Life would be arguing for the top of this board. The full field is at our provider rankings, the scoring is in how we grade, and the nearest structural comparison is our Next Health review.